Annual report
8086.TEDINET S100YJLK
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥660.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥644.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥586.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥545.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥37.6bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥26.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥19.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.5bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.3bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥29.5bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥19.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.1bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.6bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥15.7bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥1.21T | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.03T | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥930.3bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥878.5bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥858.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥334.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥311.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥269.8bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥242.2bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥199.9bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥97.8bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥106.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥88.4bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥101.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.7bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥90.1bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥54.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥72.9bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥55.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥71.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥87.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥71.7bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥8.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥22.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥43.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥82.8 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.12 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.05 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥73.36 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥60.35 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.85 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,680.71 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,547.82 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,426.56 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,265 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,135.76 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 22.6% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.0% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.1% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 38,593 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 39,168 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 38,117 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 38,770 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 36,259 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥414.7bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥393.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥368.3bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥349.7bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥331.2bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥15.1bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥8.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥15.6bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥9.7bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥19.3bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥22.3bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.5bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥18.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥6.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.7bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥844.6bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥825.7bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥808.6bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥764.9bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥727.0bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥636.7bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥629.9bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥208.0bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥195.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥187.5bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥181.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥179.7bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥17.5bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥22.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥82.57 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.54 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.1 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.47 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.87 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥73.16 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥102.37 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥37.3 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥47.38 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.82 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥29 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥27 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,275.07 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,200.51 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,149.68 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,113.64 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,102.07 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 24.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.2% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.7% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 171,459,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,714 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 4,563 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 4,388 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 4,390 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 4,252 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2025-04-01 → 2026-03-31 | ¥362m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2025-04-01 → 2026-03-31 | ¥674m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 159 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2026-03-31 | ¥7.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥6.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2026-03-31 | ¥273.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥940m |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥4.3bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥81.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥81.2bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥232.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥26.2bn |
| Medical Treatment Relatedreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥35.6bn |
| Medical Treatment Relatedreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥36.7bn |
| Medical Treatment Relatedreportable segment | employees | at 2026-03-31 | 27089 pure |
| Medical Treatment Relatedreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥530.9bn |
| Medical Treatment Relatedreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥523.6bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7.3bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2026-03-31 | ¥779.0bn |
| Medical Treatment Relatedreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥52.3bn |
| Medicine Relatedreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥25.9bn |
| Medicine Relatedreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥14.5bn |
| Medicine Relatedreportable segment | employees | at 2026-03-31 | 8271 pure |
| Medicine Relatedreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥141.7bn |
| Medicine Relatedreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥81.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥60.6bn |
| Medicine Relatedreportable segment | segment assets | at 2026-03-31 | ¥277.2bn |
| Medicine Relatedreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥12.1bn |
| Pharma Packagingreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.4bn |
| Pharma Packagingreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥5.4bn |
| Pharma Packagingreportable segment | employees | at 2026-03-31 | 2183 pure |
| Pharma Packagingreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥62.0bn |
| Pharma Packagingreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥54.7bn |
| Pharma Packagingreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7.3bn |
| Pharma Packagingreportable segment | segment assets | at 2026-03-31 | ¥116.0bn |
| Pharma Packagingreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥67.9bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥56.7bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥734.6bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥659.4bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥75.2bn |
| —segment total | segment assets | at 2026-03-31 | ¥1.17T |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥62.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥68.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥57.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥741.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥660.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥81.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.45T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥63.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥525m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥250.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥245m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥7.5bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥83.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥83.8bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥171.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥30.6bn |
| Medical Treatment Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥41.5bn |
| Medical Treatment Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥34.8bn |
| Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥512.0bn |
| Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥505.1bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2025-03-31 | ¥711.9bn |
| Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥46.6bn |
| Medicine Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥19.8bn |
| Medicine Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥15.3bn |
| Medicine Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥143.0bn |
| Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥79.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥63.8bn |
| Medicine Relatedreportable segment | segment assets | at 2025-03-31 | ¥266.4bn |
| Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥10.6bn |
| Pharma Packagingreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.7bn |
| Pharma Packagingreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Pharma Packagingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥66.1bn |
| Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥59.3bn |
| Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.8bn |
| Pharma Packagingreportable segment | segment assets | at 2025-03-31 | ¥113.4bn |
| Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥272m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥73.0bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥57.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥721.1bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥643.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥77.6bn |
| —segment total | segment assets | at 2025-03-31 | ¥1.09T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥57.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥74.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥57.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥728.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥644.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥83.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.34T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥57.2bn |
| Medical Treatment Relatedreportable segment | employees | at 2026-03-31 | 3613 pure |
| Medicine Relatedreportable segment | employees | at 2026-03-31 | 38 pure |
| Pharma Packagingreportable segment | employees | at 2026-03-31 | 172 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,141
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ia | Prior1YearInstant | 19525000000 | JPY |
| Other ia | CurrentYearInstant | 17960000000 | JPY |
| Intangible assets | Prior1YearInstant | 35505000000 | JPY |
| Intangible assets | CurrentYearInstant | 51709000000 | JPY |
| Investment securities | Prior1YearInstant | 15287000000 | JPY |
| Investment securities | CurrentYearInstant | 18902000000 | JPY |
| Net defined benefit asset | Prior1YearInstant | 2278000000 | JPY |
| Net defined benefit asset | CurrentYearInstant | 5314000000 | JPY |
| Deferred tax assets | Prior1YearInstant | 17216000000 | JPY |
| Deferred tax assets | CurrentYearInstant | 17175000000 | JPY |
| Other ioa | Prior1YearInstant | 27842000000 | JPY |
| Other ioa | CurrentYearInstant | 29183000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -5814000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentYearInstant | -6392000000 | JPY |
| Investments and other assets | Prior1YearInstant | 56812000000 | JPY |
| Investments and other assets | CurrentYearInstant | 64183000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 596145000000 | JPY |
| Noncurrent assets | CurrentYearInstant | 618458000000 | JPY |
| Assets | Prior1YearInstant | 1170564000000 | JPY |
| Assets | CurrentYearInstant | 1213290000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 83802000000 | JPY |
| Notes and accounts payable trade | CurrentYearInstant | 85345000000 | JPY |
| Short term loans payable | Prior1YearInstant | 156174000000 | JPY |
| Short term loans payable | CurrentYearInstant | 186007000000 | JPY |
| Commercial papers liabilities | Prior1YearInstant | － | JPY |
| Commercial papers liabilities | CurrentYearInstant | 10000000000 | JPY |
| Current portion of bonds | Prior1YearInstant | 1000000000 | JPY |
| Current portion of bonds | CurrentYearInstant | 1000000000 | JPY |
| Current portion of convertible bond type bonds with subscription rights to shares cl | Prior1YearInstant | － | JPY |
| Current portion of convertible bond type bonds with subscription rights to shares cl | CurrentYearInstant | 30030000000 | JPY |
| Lease obligations cl | Prior1YearInstant | 6653000000 | JPY |
| Lease obligations cl | CurrentYearInstant | 5039000000 | JPY |
| Accounts payable other | Prior1YearInstant | 30979000000 | JPY |
| Accounts payable other | CurrentYearInstant | 30511000000 | JPY |
| Income taxes payable | Prior1YearInstant | 5922000000 | JPY |
| Income taxes payable | CurrentYearInstant | 13220000000 | JPY |
| Contract liabilities | Prior1YearInstant | 1035000000 | JPY |
| Contract liabilities | CurrentYearInstant | 2332000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 9058000000 | JPY |
| Provision for bonuses | CurrentYearInstant | 14754000000 | JPY |
| Notes payable facilities | Prior1YearInstant | 4799000000 | JPY |
| Notes payable facilities | CurrentYearInstant | 2745000000 | JPY |
| Other cl | Prior1YearInstant | 51119000000 | JPY |
| Other cl | CurrentYearInstant | 47550000000 | JPY |
| Current liabilities | Prior1YearInstant | 350545000000 | JPY |
| Current liabilities | CurrentYearInstant | 428537000000 | JPY |
| Bonds payable | Prior1YearInstant | 103000000000 | JPY |
| Bonds payable | CurrentYearInstant | 103252000000 | JPY |
| Convertible bond type bonds with subscription rights to shares | Prior1YearInstant | 30090000000 | JPY |
| Convertible bond type bonds with subscription rights to shares | CurrentYearInstant | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |